Browse products
Pharma Poland News1 year subscription: (52 issues of weekly news and 12 issues of monthly analysis)
|
Our clients say...
“I have been reading Pharma Poland News of PMR Publications, on a regular basis for aprox. 2 years.
It is a valuable source of information with comments and analysis on Polish and CEE pharmaceutical markets.
Pharma Poland News is an up-to-date, comprehensive and reliable publication which I find useful as the Country Head of Schering AG in Poland. It can be, therefore, reccomended to pharma profesionals, for its quality and accuracy of information presented.”
President, Schering Polska Sp. z o.o.
“Sanofi-Aventis group regularly order PMR's reports and newsletters concerning the Polish pharmaceutical market. We use PMR's services because of the strong experience of its analysts in undertaking market analysis and a high level of quality and involvement in the field of market research. We consider PMR Ltd. a competent and professional company. PMR analysts understand our needs clearly and their services have fully met our expectations. I strongly recommend that company as a reliable partner in providing economic information and market analysis.”
General Manager, Sanofi-Synthelabo
“Pharma Poland News is the leading one among similar publications available on the market covering Polish pharmaceutical sector. This is why I decided to buy it. I like a division into weekly newsletter comprising short news, and monthly publication comprising analytical, in-depth articles with nice graphics. Another advantage is English language so there is no need to translate it for headquarters or foreign employees of the company.”
PR manager, Teva Polska
“As a Germany company doing business in Poland, we really appreciate the reliable and useful information in Pharma Poland News. Especially the information of wholesalers, pharmaceutical law changes and announcement of new products registered in Poland are quite helpful to improve our business there.”
Country Manager, Dr. Kade Pharmazeutische Fabrik GMBH
Brief description
Subscribers keep track of legal developments, new product registrations and developments in the country’s public and private healthcare systems, health insurance, and research and development activities.
In addition to coverage of the latest business and healthcare developments, Pharma Poland News contains a wealth of innovative reporting, with insight and analysis from experienced executives and expert analysts in the form of articles, interviews and commentary on the most currently important issues in the marketplace.
This newsletter is also available as an online service - Pharma Poland Online.
Compare PDF to online access.Weekly connection to industry developments
Over the years, PMR has built and maintained a network of well-placed sources that contribute to our weekly content, which includes:- News on market conditions and subsectors, trend analysis and forecasts.
- Legislative changes, the reactions of industry and patient associations, and their strategic responses to new regulations.
- Healthcare policy developments with regard to reimbursements and pricing of drugs and patient services, National Health Fund and Health Ministry actions.
- Health Technology Assessment Agency recommendations on approval of new medicines and therapies for reimbursement, levels of and conditions required for reimbursement, changes to the list of approved medications.
- Pharmaceutical company activities, including major manufacturers and distributors in the areas of wholesale pharmacy and retail chains. Read about their collaborations, new drug registrations, market plans and strategies, financial results, stock market performance and retail store openings.
- Complete coverage of the R&D sector including private healthcare data, new hospital openings, new medical devices on the marketplace, investment opportunities and mergers and acquisitions.
- Public and private healthcare market structure news, with statistical data on number of healthcare facilities, hospital beds available, medical personnel entering the field and local and international investors – including regular updates on EU funding of Poland’s healthcare modernization initiatives.
- Epidemiology reports, flu statistics and regular news stories covering market developments in the CEE countries of Bulgaria, Czech Republic, Hungary, Romania and Slovakia.
Exclusive content on a monthly basis
Because PMR is constantly involved in data gathering and market research and analysis, our publications, including the monthly in-depth issues of Pharma Poland News, contain groundbreaking and often unique information.Your business will benefit from:
- Articles that offer strategic solutions and viewpoints from top market performers and legal experts. For example, a past issue delivered a helpful article on Poland’s new Reimbursement Act, highlighting its impact on pharmaceutical companies and the possible solutions they might implement in order to craft a well-planned response and achieve more profitable results.
- Commentaries from PMR sector specialists and industry leaders representing professional associations and governmental agencies regarding market developments, future prospects and important upcoming events that are expected to influence business conditions.
- In depth interviews with newsmakers and professional analysts that delve deeply into the most current topics.
- Feature pieces on the regional market that place Poland in the context of the larger European pharmaceutical and healthcare markets. Written to promote a broader understanding of current and forecast conditions and strategic solutions, they also provide a solid basis for comparison.
- Data revisions announcing new drug registrations, withdrawals, relaunches and advertising bans.
See what is included in the weekly and monthly issues.
Business professionals rely on Pharma Poland News
PMR editors and analysts, all of whom specialize in the pharmaceutical and healthcare markets, verify the information published in every issue of Pharma Poland News for accuracy. Because a clear understanding of the legal and regulatory environment is so critical to success in pharma, they regularly consult with pharmaceutical law firms for commentary, insight and content verification.Our long-term subscribers include:
- Executives at leading regional and international pharmaceutical, insurance and consulting companies
- Professionals at firms that manufacture and distribute medical supplies
- Foreign investors in the Polish pharmaceutical market
- Government agency personnel
- Researchers at universities and institutes of science
- Pharmaceutical and healthcare industry professional organizations
- Banks, brokerage firms and other financial institutions with an interest in market performance
These professionals trust the content of Pharma Poland News as their strategic basis, and so can you. Subscribe today!
Request more info/free trial
Pharma Poland News
1 year subscription: (52 issues of weekly news and 12 issues of monthly analysis)
Choose your version of this product:
| Language / Licence | Single | 5 Users | Corporate | Global |
| English | 950€ | 1380€ | 2100€ | 2800€ |
Compare licences
- - for the product preservation: saving the product in the memory of one computer belonging to the client;
- - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for the individual use of one person only, who is indicated by the client during purchasing process.
Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
- - for the product preservation: saving the product in the memory of 2 to 5 computers belonging to the organisation indicated by the client while purchasing process; these computers must be located in the same country as the organisation indicated during purchasing process;
- - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for 2 to 5 people who work for the organisation indicated by the client during purchasing process, and who are in the same country as the organisation indicated during purchasing process.
Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
- - for the product preservation: saving the product in the memory of an unlimited number of computers belonging to the organisation indicated by the client during purchasing process; these computers must be located in the same country as the organisation indicated during purchasing process;
- - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for an unlimited number of people who work for the organisation indicated by the client during purchasing process, who are in the same country as the organisation indicated during purchasing process.
Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
- - for the product preservation: saving the product in the memory of an unlimited number of computers belonging to the organisation indicated by the client during purchasing process; these computers can be located in or outside of the country of the organisation indicated during purchasing process;
- - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for an unlimited number of people who work for the organisation indicated by the client during purchasing process, who are in or outside of the country of the organisation indicated during purchasing process.
Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.